J&J snaps up stroke-reducing heart implant

Today’s Big News

Nov 30, 2023

AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field


After watching Merck's chronic cough drama, GSK knew exactly what not to do with Bellus asset


J&J drops $400M to acquire new type of stroke-reducing heart implant 


Pfizer site in Connecticut in line for layoffs amid $3.5B cost-cutting campaign


Bayer taps CrossBay’s uterus access device to make IUD placements less painful


Endo brings men to the pool hall for straight talk on Peyronie's in latest Xiaflex push

 

Featured

AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field

The sizzling antibody-drug conjugate field is at the center of another major life sciences deal. Hoping to redeem itself following the epic Rova-T failure, AbbVie is shelling out $10.1 billion in cash to acquire ImmunoGen, maker of the ovarian cancer treatment Elahere.
 

Top Stories

After watching Merck's chronic cough drama, GSK knew exactly what not to do with Bellus asset

By the time GSK sealed the deal on Bellus Health in April, the U.K. pharma knew exactly what not to do with the phase 3 chronic cough program. The company had watched Merck & Co. struggle with a rival med called gefapixant, taking notes.

J&J drops $400M to acquire new type of stroke-reducing heart implant

Johnson & Johnson MedTech has spent $400 million upfront to purchase Laminar, the designer of a device under development for closing off the heart’s left atrial appendage, where blood clots can form to increase the risk of stroke in people with afib.

Pfizer site in Connecticut in line for layoffs amid $3.5B cost-cutting campaign

The company's Groton, Connecticut, research site is the latest to fall victim to job cuts as part of Pfizer's massive $3.5 billion cost-cutting mission, following layoffs across the U.S. and the U.K.

Bayer taps CrossBay’s uterus access device to make IUD placements less painful

CrossBay’s approach does away with the metal forceps typically needed to reach the inner uterus and has collected clearances in endometrial biopsies and IVF procedures.

Endo brings men to the pool hall for straight talk on Peyronie's in latest Xiaflex push

Endo is taking its Peyronie's disease campaign from the vegetable aisle to the pool hall. Having initially relied on wonky veg to discuss the men’s health condition, the drugmaker has now brought four people with Peyronie's together to shoot some pool and chat about their experiences.

Phenomic AI inks second deal in two days, Shape stretches Roche collab

Phenomic AI went from radio silence to two deals in two days, this time signing an antibody-focused pact with Astellas. ShapeTX has also been busy, expanding an existing collaboration with Roche to tack on another target.

First surgical patients treated with CMFlex 3D-printed regenerative bone graft

Several months after earning FDA clearance, a 3D-printed bone graft product is gaining steam, having now been used in a handful of surgical procedures.

Fighting unauthorized GLP-1 knockoffs, Novo Nordisk files 2 new lawsuits against Florida companies

Seven weeks after a federal judge dismissed a Novo Nordisk’s lawsuit, which accused a Florida pharmacy of selling unauthorized knockoffs of its GLP-1 Wegovy, Ozempic and Rybelsus, Novo has sued the same company. Brooksville Pharmaceuticals is the target of a refiled Novo lawsuit, this one claiming there are impurities in the company’s compounded versions of the popular weight loss treatments. Also facing the same complaint is another Florida company, Wells Pharmacy.

AbbVie’s lung cancer data light path to ADC accelerated approval but fall short of earlier benchmark

AbbVie has its eyes on accelerated approval of its c-Met antibody-drug conjugate (ADC). The candidate achieved a 35% response rate in a subset of lung cancer patients, spurring plans to talk to regulators, but unfavorable comparisons to an earlier data drop partly took the shine off the update.
 
Fierce podcasts

Don’t miss an episode

Alzheimer’s breakthroughs, Leqembi's potential and what's next

This episode of "The Top Line" is dedicated to Alzheimer’s disease, spotlighting the latest treatments and what lies ahead. Fierce Pharma's Fraiser Kansteiner discusses Leqembi's full approval with Eisai's Alexander Scott. Annalee Armstrong from Fierce Biotech interviews Alzheimer's expert Howard Fillit, M.D., exploring groundbreaking research. Fierce Pharma’s Eric Sagonowsky speaks with Reisa Sperling, M.D., about Leqembi's potential in preventing Alzheimer’s progression before symptoms emerge.

 

Resources

Whitepaper

Accelerate drug discovery with high-performance computing (HPC) powered by the cloud

Accelerate drug discovery with high-performance computing (HPC) powered by the cloud
Whitepaper

Effective Technology Transfers for Mammalian-Derived Biologics

As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. 

eBook

An Introduction to Organ-on-a-Chip Technology

Emulate in vivo biology with next-generation in vitro technology.
Whitepaper

Overcome Challenges and Secure Successful Technology Transfers of Complex Biological Products in Sterile Manufacturing

A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer.

Whitepaper

Enhance the cost-effectiveness of your GMP chemical supply chain

Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows.
Whitepaper

Plasmid DNA Design Considerations for Cell and Gene Therapy

Download our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications.
Whitepaper

Artificial Intelligence in Healthcare & Medical Affairs

This paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders.
 

Industry Events

Genesis 2023

 

Upcoming Fierce Events

5
Dec
Edison Ballroom, New York City
9-10
Jan
San Francisco, CA
16-18
Jan
Virtual Event
11-12
Mar
San Francisco, CA
18-20
Mar
Savannah, GA

View all events